Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer

Gene Therapy

Volumn 21, Issue 8, 2014, Pages 723-731

  Yang, Y F ^a   Xue, S Y ^a   Lu, Z Z ^b   Xiao, F J ^a   Yin, Y ^c   Zhang, Q W ^a   Wu, C T ^a   Wang, H ^a   Wang, L S ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; PROSTATE SPECIFIC ANTIGEN;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; GENE FUSION; GENE THERAPY; GENETICS; HELA CELL LINE; HUMAN; MALE; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PROCEDURES; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CD40 LIGAND; CELL LINE, TUMOR; GENE FUSION; GENETIC THERAPY; HELA CELLS; HUMANS; MALE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84905922749     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.46     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Cannata DH, Kirschenbaum A, Levine AC. Androgen deprivation therapy as primary treatment for prostate cancer. J Clin Endocrinol Metab 2012; 97: 360-365.
3. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011; 8: 357-368.
4. Banchereau J, Paczesny S, Blanco P, Bennett L, Pascual V, Fay J et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann NY Acad Sci 2003; 987: 180-187.
5. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004; 104: 2235-2246.
6. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009; 229: 152-172.
7. Xu Y, Song G. The role of CD40-CD154 interaction in cell immunoregulation. J Biomed Sci 2004; 11: 426-438.
8. Hildenbrand B, Sauer B, Kalis O, Stoll C, Freudenberg MA, Niedermann G et al. Immunotherapy of patients with hormone-refractory prostate carcinoma pretreated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells-a pilot study. Prostate 2007; 67: 500-508.
9. Williams BJ, Bhatia S, Adams LK, Boling S, Carroll JL, Li XL et al. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector. PLoS One 2012; 7: e46981.
10. Dzojic H, Loskog A, Tötterman TH, Essand M. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Prostate 2006; 66: 831-838.
11. von Euler H, Sadeghi A, Carlsson B, Rivera P, Loskog A, Segall T et al. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J Immunother 2008; 31: 377-384.
12. Xu W, Li Y, Wang X, Wang C, ZhaoW, Wu J. Anti-tumor activity of gene transfer of the membrane-stable CD40L mutant into lung cancer cells. Int J Oncol 2010; 37: 935-941.
13. Zhang L, Tang Y, Akbulut H, Zelterman D, Linton PJ, Deisseroth AB. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc Natl Acad Sci USA 2003; 100: 15101-15106.
14. Toth K, Dhar D, Wold WS. Oncolytic (replication-competent) adenoviruses as anticancer agents. Expert Opin Biol Ther 2010; 10: 353-368.
15. Freytag SO, Stricker H, Movsas B, Kim JH. Prostate cancer gene therapy clinical trials. Mol Ther 2007; 15: 1042-1052.
16. Tuve S, Liu Y, Tragoolpua K, Jacobs JD, Yumul RC, Li ZY et al. In situ adenovirus vaccination engages T effector cells against cancer. Vaccine 2009; 27: 4225-4239.
17. Alemany R. A smart move against cancer for vaccinia virus. Lancet Oncol 2008; 9: 507-508.
18. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010; 70: 4297-4309.
19. Tokmadžić VS, Tomaš MI, Sotošek S, Laškarin G, Dominović M, Tulić V et al. Different perforin expression in peripheral Blood and prostate tissue in patients with benign prostatic hyperplasia and prostate cancer. Scand J Immunol 2011; 74: 368-376.
20. Nencioni A, Grünebach F, Schmidt SM, Müller MR, Boy D, Patrone F et al. The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 2008; 65: 191-199.
21. Aalamian M, Pirtskhalaishvili G, Nunez A, Esche C, Shurin GV, Huland E et al. Human prostate cancer regulates generation and maturation of monocyte derived dendritic cells. Prostate 2001; 46: 68-75.
22. Pirtskhalaishvili G, Shurin GV, Esche C, Cai Q, Salup RR, Bykovskaia SN et al. Cytokine mediated protection of human dendritic cells from prostate cancer induced apoptosis is regulated by the Bcl-2 family of proteins. Br J Cancer 2000; 83: 506-513.
23. Cheng WS, Dzojic H, Nilsson B, Tötterman TH, Essand M. An oncolytic conditionally replicating adenovirus for hormone-dependent and hormoneindependent prostate cancer. Cancer Gene Ther 2006; 13: 13-20.
24. Lee SJ, Kim HS, Yu R, Lee K, Gardner TA, Jung C et al. Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol Ther 2002; 6: 415-421.
25. Hu ZB, Wu CT, Wang H, Zhang QW, Wang L, Wang RL et al. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Cancer Gene Ther 2008; 15: 173-182.